Empagliflozin use in cardiac transplant patients: Real world experience from Saudi Arabia

Empagliflozin use in cardiac transplant patients Real world experience from Saudi Arabia

Objectives: Sodium-glucose transport protein 2 inhibitor |(SGLT2) drugs are used to treat patients with type 2 diabetes. In additions to their beneficial metabolic effects in lowering the glaciated hemoglobin, body weight and blood pressure, these agents have shown favorable and protective effects o...

Full description

Saved in:
Bibliographic Details
Published in:Sultan Qaboos University medical journal
Main Authors: Butt, Muhammad I, Albalwi, Roaa MH, Alnassar, Norah, Alghambi, Reem
Format: Journal Article
Language:English
Published: 31-10-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: Sodium-glucose transport protein 2 inhibitor |(SGLT2) drugs are used to treat patients with type 2 diabetes. In additions to their beneficial metabolic effects in lowering the glaciated hemoglobin, body weight and blood pressure, these agents have shown favorable and protective effects on the heart and the kidneys. These cardio renal benefits are seen even in people without diabetes. There is little evidence on the safety and efficacy of SGLT2 inhibitors use in cardiac transplant recipients. We wanted to study the cardiac transplant recipients who used Empagliflozin for the treatment of diabetes to evaluate its safety and efficacy in this niche sub group of patients. Method: We retrospectively identified 20 patients on the cardiac transplant recipient register taking Empagliflozin (Jardiance) or Empagliflozin combined with Metformin (Synjardy). We studied the safety and efficacy parameters. Results: Our results show improvement in HBA1c, body weight and stability in serum creatinine. There was no increased risk of genitourinary infection, hypoglycemia or diabetic ketoacidosis. Conclusion: While we need larger studies in cardiac transplant patients taking Empagliflozin, our small study provides assurance that Empagliflozin is safe to use in cardiac transplant recipients.
ISSN:2075-0528
2075-0528
DOI:10.18295/squmj.10.2024.057